Hims & Hers launch of compounded $49 Wegovy pill pummeled Novo Nordisk’s shares

Last Updated: Feb. 5, 2026 at 4:08 p.m. ET
First Published: Feb. 5, 2026 at 10:56 a.m. ET

Hims & Hers Health launched a cheaper, compounded version of the new Wegovy pill in a move that reignites its competition with Novo Nordisk in the U.S. obesity-drug market.

Shares of of Hims & Hers HIMS rose 11% at market open on Thursday morning but later closed 3.8% down, while U.S.-listed shares of Novo Nordisk NVO ended up closing 8.1% lower. That’s its lowest closing price since July 16, 2021.